Inclusion Criteria

Inclusion Criteria

- Histologically or cytologically confirmed diagnosis of non-Hodgkin's lymphoma (NHL)

- Subjects must have received prior chemotherapy for their NHL

- At least 18 years of age

- Bidimensionally measurable disease amenable to CT scanning. At least one lesion must
be least 1 X 1 cm in size.

- Karnofsky performance status of at least 70%

- Estimated life expectancy of at least 12 weeks

- Females of childbearing potential must have a negative pregnancy test and agree to
use an effective contraceptive

- Subject must be able to comply with study procedures and follow-up examinations.

- Signed written informed consent

- Lab Values (obtained ≤ 7 days prior to study enrollment):

- ANC at least 1.5x10e9/L,

- Platelet count at least 100x10e9/L,

- Hemoglobin at least 8.5 g/dL,

- Creatinine within 2 times upper limit of normal,

- AST and ALT within 3 times upper limit of normal,

- Bilirubin within 1.5 times upper limit of normal,

- Albumin great than 2.5 g/dL,

Exclusion Criteria

- Severe, concurrent disease, infection or co-morbidity that, in the judgment of the
investigator, would make the subject inappropriate for enrollment

- NYHA Class III/IV cardiac disease, left ventricular ejection fraction (LVEF) of <50%,
or acute anginal symptoms

- Patients who have received any investigational agent within 4 weeks of enrollment

- Patients who are pregnant or breast-feeding

- History of prior malignancy other than NHL within the last 5 years, except for
adequately treated basal cell or squamous cell skin cancer or carcinoma in situ of
the cervix

- History of central nervous system metastases or carcinomatous meningitis

- Major surgery within 4 weeks of enrollment